Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Imetelstat provides durable transfusion independence in lower risk MDS group

Pierre Fenaux • 14 Jun 2019
EHA 2019
Myelodysplastic Syndromes Imetelstat

In this press briefing, recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Pierre Fenaux of St Louis Hospital, Paris, France, presents data on the use of imetelstat in lower risk myelodysplastic syndrome (MDS) patients. Treatment with imetelstat, a telomerase inhibitor, was shown to provide durable transfusion independence in heavily transfused non-del(5q) lower risk MDS that is relapsed/refractory to erythropoietic stimulating agents.

More from Pierre Fenaux

4:01
The role of patients and patient groups in the European Reference Network EuroBloodNet
Joan Lluis Vives-Corrons et al. • 9 Jun 2016
3:13
An overview of the European Reference Networks and EuroBloodNet
Joan Lluis Vives-Corrons et al. • 9 Jun 2016
3:16
EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?
Joan Lluis Vives-Corrons et al. • 9 Jun 2016

Related Videos

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
2:37
Allo-SCT in older patients with MDS: selection, donors, and timing
Didier Blaise • 4 Apr 2024
1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
The content of VJHemOnc is intended for healthcare professionals